Sarasota Medical Products, Inc. Celebrates 15 Years of Innovation, Partnership, and Purpose in Medical Adhesives
Sarasota Medical Products, Inc. (SMP), a veteran-owned innovator in the field of medical device adhesives, is proudly celebrating its 15th anniversary. It is a milestone that reflects its unwavering commitment to innovation, trusted partnership, and elevating the standard of care for patients worldwide.
Founded in 2010 by Dr. Walter Francis Leise III, SMP began as an ambitious idea on paper, an MBA business plan, and a leap of faith away from corporate life. Today, the company stands as a recognized innovator in custom hydrocolloid development and wound, ostomy, and incontinence care, with a legacy of breakthroughs, partnerships, and purpose-driven growth.
The turning point in SMP's early days came unexpectedly on Christmas Eve in 2011. Dr. Leise was in the lab, frustrated by an adhesive formulation that didn't meet expectations. But inspiration struck the next morning.
'I realized the formulation could actually serve a completely different need,' he said. 'It turned out to be perfect as a moldable gasket for ostomy patients. That moment really encapsulated what we now do: adapt, innovate, and listen to what patients need.' That adaptability became the cornerstone of SMP's success.
SMP closely works with partners to develop customized, premium adhesive solutions. Each formulation is created with patients in mind. 'We're not a 'take it or leave it' company,' said Dr. Leise. SMP dwells on the philosophy that good products come from great partnerships. It only works with vendors who want to be partners, not just buyers. And the SMP team speaks to the patients constantly to hear them out, especially if something's not working, and constantly works on innovation. This commitment has led them to key acquisitions and brand expansions that reinforce SMP's standing in the market.
In 2019, SMP acquired Cymed, a premium brand tailored for active patients. Employing micro skin, a breathable, ultra-thin, water-resistant adhesive dressing, Cymed empowers users to move freely, exercise, swim, and live without limits. 'Cymed is for people who don't want to slow down,' said Dr. Leise. 'It's one of the oldest names in ostomy care, and we're proud to carry it forward with next-gen improvements.'
In 2020, SMP acquired Entrust, now housed under its Fortis Medical Products division. Known for high-quality ostomy, ileostomy, and urostomy devices, Entrust was brought under the SMP umbrella during the COVID-19 crisis, preserving a trusted brand and giving it the operational strength to grow.
'With Entrust, the mission is trust,' said Dr. Leise. 'Patients deserve to forget they've had a life-changing surgery. Our job is to make products so dependable and comfortable, their dignity and quality of life are never in question.'
Based in Florida, SMP maintains its U.S.-made advantage, allowing it to maintain cost-competitive pricing against Asian manufacturers, all while offering unmatched customization and quality. Innovations in process efficiency have further strengthened SMP's position. The company has developed proprietary methods that dramatically reduce labor requirements and production costs, without compromising product performance. These efficiencies enable SMP to keep prices low, expand globally, and reinvest in research and development, including groundbreaking ventures into antibacterial adhesives.
Looking ahead, SMP is launching a new brand, Ndur Healthcare, featuring a skincare line powered by natural ingredients like tallow, alongside anti-aging and acne care innovations. A major highlight is Magic Shields, a patented, FDA-approved, silver-free antibacterial hydrocolloid that kills MRSA and E. coli, reduces fungal infections, and supports wound healing. Magic Shields is designed to serve both skincare and wound care needs, showcasing SMP's expanding footprint in preventive health.
Over the past decade and a half, SMP has gone from a single formulation to hundreds of private-label products, serving more than 20 companies. 'I'm proud we're still here,' said Dr. Leise. 'It's easy to underestimate the grit it takes to survive and grow in this industry. But I believe in working hard every day so that when luck comes, we're ready for it.'
As Sarasota Medical Products celebrates this 15-year milestone, the company remains anchored in its mission: to empower patients to live confidently, comfortably, and with dignity, one innovative adhesive at a time.
Media Contact
Name: Rachel Crumbley
Email: [email protected]
The content provided herein does not constitute medical advice. Any references to treatments, products, or services are not intended as endorsements. The company and its affiliates are not responsible for the accuracy, reliability, effectiveness, or correct use of information contained in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Elliott Statement on Southwest Governance Changes
WEST PALM BEACH, Fla. , July 31, 2025 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott") today released the following statement on behalf of Partner John Pike and Portfolio Manager Bobby Xu regarding Rakesh Gangwal's decision to step down from his role as Chair at Southwest Airlines Co. (NYSE: LUV) (the "Company" or "Southwest"): We thank Mr. Gangwal for his leadership and contributions as Southwest's independent Chair during a transformational period for the company and we are grateful that he will continue to serve as a member of the Board. We remain confident in Southwest's trajectory and we look forward to continuing our constructive engagement as the Company executes its plan to drive long-term value. About Elliott Elliott Investment Management L.P. (together with its affiliates, "Elliott") manages approximately $72.7 billion of assets as of December 31, 2024. Founded in 1977, it is one of the oldest funds under continuous management. The Elliott funds' investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Media Contact: Casey Friedman Elliott Investment Management L.P. (212) 478-1780 cfriedman@ View original content to download multimedia: SOURCE Elliott Investment Management L.P. Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
Investors react to Trump's new reciprocal tariffs announcement
SINGAPORE (Reuters) -President Donald Trump signed an executive order on Thursday imposing reciprocal tariffs ranging from 10% to 41% on U.S. imports from dozens of countries and foreign locations. Rates were set at 25% for India's U.S.-bound exports, 20% for Taiwan's and 30% for South Africa's. Trump also signed an executive order on Thursday increasing tariffs on Canadian goods to 35% from 25%, the White House said. QUOTES: TONY SYCAMORE, MARKET ANALYST, IG, SYDNEY: "At this point, the reaction in markets has been modest, and I think part of the reason for that is the recent trade deals with the EU, Japan, and South Korea have certainly helped to cushion the impact, as has Mexico being granted a 90-day reprieve. And Trump said that trade talks with China are doing reasonably well there. "So on top of all of that, you have the TACO trade type situation whereby, after being obviously caught on the wrong foot in April, the market now, I think, has probably taken the view that these trade tariff levels can be renegotiated, can be walked lower over the course of time." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, MENOMONEE FALLS, WISCONSIN (emailed comment): "Just because we now have clarity on the tariffs, that doesn't mean we have certainty about their effects. "There are those who think that tariff-induced consumer price inflation will slowly build as businesses work down inventories and test how strong their pricing power is. Others think the tariff-induced inflation will peak earlier, showing up mostly in crimped profit margins and resulting in slower growth. "However, what tariffs take with one hand, maybe tax incentives to invest and more open foreign markets can give with the other hand."
Yahoo
6 minutes ago
- Yahoo
Trump doubles down on Most Favored Nation plan to target drug prices
US President Donald Trump has called on pharmaceutical manufacturers to lower US drug prices in line with the Most Favored Nation (MFN) policy first proposed in an executive order in May. On 31 July, the White House said letters were sent to leading pharmaceutical manufacturers like AstraZeneca, AbbVie, Eli Lilly, Regeneron, Novartis, Pfizer, and more, calling on them to take steps to lower drug prices in the US such that they match the lowest prices in other developed countries within the next 60 days. President Trump also shared many of these letters on the social media platform Truth Social. While this is not the first time the administration has floated the MFN policy, this time, the language used to address pharma companies is more aggressive. If the companies do not comply, the order states, the federal government 'will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' In response to this statement, a spokesperson for the industry body BIO said, 'We share the Administration's goal of ending foreign freeloading on American innovation. But importing socialist price controls would lead only to fewer new medicines and the rationing of healthcare for Americans and would strengthen and embolden foreign adversaries whose goal is to dominate the world in biotechnology.' The BIO spokesperson said eliminating the middlemen, ending the abuse of drug reimbursement programs like 340B would be a way to simplify the system, protect patients and narrow the pricing gap between the US and other developed countries. 'Middlemen' or pharmacy benefit managers (PBMs) are often blamed by the pharmaceutical companies for high drug prices. PBMs on their part have said they negotiate with different stakeholders to drive down costs, and pass on savings obtained through rebates and discounts to health plans. The letter to the manufacturers implores them to provide drug at 'MFN rates' to all Medicaid patients, and commit to providing these prices for newly launched drugs to all major US buyers like Medicare and commercial plans. The latest announcement also calls on drug manufacturers to opt in for platforms where drugs can be sold directly to patients at prices that are comparable to those in developed nations, which are currently offered to third party payers. Among the letters posted on Truth Social, Trump directly called on several CEOs like Albert Bourla of Pfizer, and Leonard Schleifer of Regeneron, by using their first names instead of a formal address. Several countries use international reference pricing as a strategy in their health systems. However, chief among the criticism following the May executive order has been the lack of details. Industry experts have highlighted a lack of clarity on how any potential list price changes will affect the prices patients pay at the pharmacy counter given the complex dynamics and multiple stakeholders in the US healthcare system. There is also a concern that if the US implements reference pricing, it could influence when companies choose to launch drugs in certain ex-US markets to avoid those potentially lower prices from being used as references. Furthermore, pharma companies have chosen the litigation route to fight legislative changes targeting drug prices, like the Inflation Reduction Act, and the same could be seen with the MFN executive order, as per a Bank of America report. "Trump doubles down on Most Favored Nation plan to target drug prices" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合
